NCT02788721View on ClinicalTrials.gov

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 14, 2016

Primary Completion Date

April 27, 2017

Study Completion Date

April 27, 2017

Conditions
Healthy
Interventions
DRUG

GLPG2451 single dose

GLPG2451 oral suspension, single ascending doses, daily

DRUG

Placebo

Placebo, oral suspension, daily

Trial Locations (1)

Unknown

SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
collaborator

Pharmaceutical Research Associates

OTHER

collaborator

SGS S.A.

INDUSTRY

lead

Galapagos NV

INDUSTRY